StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.16 | $1.10 | -5.17% | 3.3M |
| 05-12 | $1.11 | $1.07 | -3.60% | 2.3M |
| 05-13 | $1.05 | $1.04 | -0.95% | 4.0M |
| 05-14 | $1.03 | $1.20 | +16.50% | 5.8M |
| 05-15 | $1.17 | $1.08 | -7.26% | 2.5M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
Fundamentals not available for CYPH.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Annual 2021 2021-12-31 | Q3 2021 2021-09-30 | Q2 2021 2021-06-30 | Q1 2021 2021-03-31 |
|---|---|---|---|---|
Revenue | $1.50M | $1.13M | $750.00K | $375.00K |
Operating Income | $-41.43M | $-30.94M | $-18.80M | $-9.17M |
Net Income | $-40.59M | $-29.80M | $-18.66M | $-9.13M |
EPS (Diluted) | $-0.47 | $-0.39 | $-0.24 | $-0.12 |
Total Assets | $117.91M | $128.08M | $37.94M | $45.81M |
Total Liabilities | $10.02M | $11.26M | $8.06M | $7.43M |
Cash & Equivalents | $114.92M | $124.77M | $35.73M | $43.49M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 59.66M | 87.84M | 59.67M | 59.67M |
No sell-side coverage available for CYPH.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.